In the past twelve months, regenerative medicine investments gained momentum, as new and promising clinical data got released. The momentum has been growing in recent years, enabling the cell therapy and genome editing sectors to evolve into a global industry.
Cord Blood World Europe – Bringing together Public and Private Banks, Clinicians & Researchers
BioInformant is excited and proud to announce our sponsorship of the Cord Blood World Europe Congress 2015 as an essential global event for those participating within the cord blood and regenerative medicine community. BioInformant is deeply committed to advancing progress with human umbilical cord blood, because cord blood contains valuable hematopoietic stem cells and cord tissue (“Wharton’s Jelly”) contains valuable mesenchymal stem cells.
As the first and only company dedicated to tracking the stem cell market, BioInformant tracks this important market segment within our global strategic report the “Complete 2015-16 Global Cord Blood Industry Report.” We also have an entire section of our blog dedicated to breaking cord blood industry news. Additionally, we have a partnership with the Save the Cord Foundation, a non-profit dedicated to cord blood banking awareness and education, in which we run a joint awareness campaign called “Cord Blood Banking Awareness: Educating America and the World.” The campaign is a global effort to educate currently expecting parents, as well as future parents, grandparents, siblings, and friends, about the medical benefits of cord blood preservation. [Read more…]
WideCells – Stem Cell Biotechnology and Regenerative Medicine in the 21st Century
WideCells is a new and innovative stem cell technology and regenerative medicine company. It was founded by the CEO João Andrade and the CFO Lopes Gil. Dr Peter Hollands later joined as CSO bringing experience from other UK and international stem cell banks, clinical transplantation, teaching and research.
The first operations for WideCells were in Portugal, following on to the acquisition of the Spanish company Nacersalud to begin operations in Spain.
The continued success of operations in Portugal and Spain has led to the development of [Read more…]
BioInformant iPS Cell Data Featured on Centre for Commercialization of Regenerative Medicine
BioInformant is excited to share that our induced pluripotent stem cell industry analytics have been featured on the “Signals Blog,” published by the Centre for Commercialization of Regenerative Medicine (CCRM). CCRM is a Canadian, not-for-profit organization supporting the development of foundational technologies that accelerate the commercialization of stem cell- and biomaterials-based products and therapies.
The post, titled Right Turn: Commercializing iPSCs – Infographics, states: “The beauty of an infographic (or two) is it speaks for itself.”
View Full CCRM Post
My Story: Founder of a Stem Cell Market Research Firm and a Stem Cell Patient
For the past 15 years, I have studied stem cells, including technology and research advances, as well as market trends. I have been fascinated with them for most of my adult life, founding BioInformant as the first and only market research firm to specialize in the stem cell industry.
As a result of this decision, I have had the honor of serving thousands clients from across the stem cell industry and been interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine.
However, it was only recently that I experienced the power of stem cells to impact my own life and health.